Agios Pharma (AGIO) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AGIO Analyst Ratings

Strong Buy

5 Buy

1 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Agios

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AGIO Stock 12 Month Forecast

Average Price Target

$844.50

▼(-30.89% Downside)

Based on 6 Wall Street analysts offering 12 month price targets for Agios Pharma in the last 3 months. The average price target is $844.50 with a high forecast of $1,027.60 and a low forecast of $597.87. The average price target represents a -30.89% change from the last price of $1,222.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"596":"$596","1223":"$1,223","752.75":"$752.8","909.5":"$909.5","1066.25":"$1,066.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1027.595613,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.03K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":844.49675832,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$844.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":597.8738112,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$597.87</span>\n  </div></div>","useHTML":true}}],"tickPositions":[596,752.75,909.5,1066.25,1223],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1222,1207.0458163846154,1192.0916327692307,1177.137449153846,1162.1832655384615,1147.2290819230768,1132.2748983076922,1117.3207146923078,1102.3665310769231,1087.4123474615385,1072.4581638461539,1057.5039802307692,1042.5497966153846,{"y":1027.595613,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1222,1192.9612891015386,1163.922578203077,1134.8838673046155,1105.8451564061538,1076.8064455076924,1047.7677346092307,1018.7290237107693,989.6903128123076,960.6516019138462,931.6128910153845,902.5741801169231,873.5354692184616,{"y":844.49675832,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1222,1173.9902931692309,1125.9805863384615,1077.9708795076922,1029.961172676923,981.9514658461538,933.9417590153846,885.9320521846154,837.9223453538461,789.9126385230769,741.9029316923077,693.8932248615384,645.8835180307692,{"y":597.8738112,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1222,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1222,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1222,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1222,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1222,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1222,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1222,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1222,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1222,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1222,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1222,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1222,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1222,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$1,028

Average Price Target$844.50

Lowest Price Target$597.87

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Samantha Semenkow

Citi

$971.54

Buy

-20.50%

Downside

Reiterated

10/28/26

Citi Keeps Their Buy Rating on Agios Pharma (AGIO)

Luca Issi

RBC Capital

$597.87

Hold

-51.07%

Downside

Reiterated

10/08/26

Agios Pharma (AGIO) Gets a Hold from RBC Capital

Gregory Renza

Truist Financial

$728.66→$691.29

Buy

-43.43%

Downside

Reiterated

10/07/26

Agios Pharmaceuticals price target lowered to $37 from $39 at TruistAgios Pharmaceuticals price target lowered to $37 from $39 at Truist

Alec Stranahan

Bank of America Securities

$934.18

Buy

-23.55%

Downside

Reiterated

10/06/26

Analysts Offer Insights on Healthcare Companies: Agios Pharma (NASDAQ: AGIO), Korro Bio (NASDAQ: KRRO) and HeartBeam (NASDAQ: BEAT)

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

08/03/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Agios Pharma (NASDAQ: AGIO), Novavax (NASDAQ: NVAX) and Keros Therapeutics (NASDAQ: KROS)

Emily Bodnar

H.C. Wainwright

$971.54→$1,027.6

Buy

-15.91%

Downside

Reiterated

07/30/26

Agios Pharmaceuticals price target raised to $55 from $52 at H.C. WainwrightAgios Pharmaceuticals price target raised to $55 from $52 at H.C. Wainwright

Salveen Richter

Goldman Sachs

$597.87

Hold

-51.07%

Downside

Reiterated

07/21/26

Analysts Offer Insights on Healthcare Companies: Agios Pharma (NASDAQ: AGIO) and Imunon (NASDAQ: IMNN)

Andrew Berens

Leerink Partners

―

Buy

―

Reiterated

07/07/26

Analysts Offer Insights on Healthcare Companies: Oncology Institute (NASDAQ: TOI) and Agios Pharma (NASDAQ: AGIO)

Tessa Romero

J.P. Morgan

$672.61→$579.19

Hold

-52.60%

Downside

Assigned

06/11/26

Analysts Are Neutral on Top Healthcare Stocks: Stevanato Group (STVN), Agios Pharma (AGIO)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Samantha Semenkow

Citi

$971.54

Buy

-20.50%

Downside

Reiterated

10/28/26

Citi Keeps Their Buy Rating on Agios Pharma (AGIO)

Luca Issi

RBC Capital

$597.87

Hold

-51.07%

Downside

Reiterated

10/08/26

Agios Pharma (AGIO) Gets a Hold from RBC Capital

Gregory Renza

Truist Financial

$728.66→$691.29

Buy

-43.43%

Downside

Reiterated

10/07/26

Agios Pharmaceuticals price target lowered to $37 from $39 at TruistAgios Pharmaceuticals price target lowered to $37 from $39 at Truist

Alec Stranahan

Bank of America Securities

$934.18

Buy

-23.55%

Downside

Reiterated

10/06/26

Analysts Offer Insights on Healthcare Companies: Agios Pharma (NASDAQ: AGIO), Korro Bio (NASDAQ: KRRO) and HeartBeam (NASDAQ: BEAT)

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

08/03/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Agios Pharma (NASDAQ: AGIO), Novavax (NASDAQ: NVAX) and Keros Therapeutics (NASDAQ: KROS)

Emily Bodnar

H.C. Wainwright

$971.54→$1,027.6

Buy

-15.91%

Downside

Reiterated

07/30/26

Agios Pharmaceuticals price target raised to $55 from $52 at H.C. WainwrightAgios Pharmaceuticals price target raised to $55 from $52 at H.C. Wainwright

Salveen Richter

Goldman Sachs

$597.87

Hold

-51.07%

Downside

Reiterated

07/21/26

Analysts Offer Insights on Healthcare Companies: Agios Pharma (NASDAQ: AGIO) and Imunon (NASDAQ: IMNN)

Andrew Berens

Leerink Partners

―

Buy

―

Reiterated

07/07/26

Analysts Offer Insights on Healthcare Companies: Oncology Institute (NASDAQ: TOI) and Agios Pharma (NASDAQ: AGIO)

Tessa Romero

J.P. Morgan

$672.61→$579.19

Hold

-52.60%

Downside

Assigned

06/11/26

Analysts Are Neutral on Top Healthcare Stocks: Stevanato Group (STVN), Agios Pharma (AGIO)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AXGNAxoGen

SIBNSI-Bone

AORTArtivion

PHVSPharvaris

HELPHelus Pharma

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Agios Pharma

3 Months

Marc FrahmTD Cowen

Success Rate

16/23 ratings generated profit

Average Return

+5.60%

Copying Marc Frahm's trades and holding each position for 3 Months would result in 69.57% of your transactions generating a profit, with an average return of +5.60% per trade.

1 Year

Gregory RenzaTruist Financial

Success Rate

20/30 ratings generated profit

Average Return

+20.05%

Copying Gregory Renza's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +20.05% per trade.

2 Years

Gregory RenzaTruist Financial

Success Rate

23/30 ratings generated profit

Average Return

+16.17%

Copying Gregory Renza's trades and holding each position for 2 Years would result in 76.67% of your transactions generating a profit, with an average return of +16.17% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AGIO Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AGIO has received 6 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. AGIO average Analyst price target in the past 3 months is 844.50.

Each month's total comprises the sum of three months' worth of ratings.

AGIO Financial Forecast

AGIO Earnings Forecast

Next quarter’s earnings estimate for AGIO is -$23.26 with a range of -$30.64 to -$19.80. The previous quarter’s EPS was -$31.58. AGIO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year AGIO has Performed in-line its overall industry.

AGIO Sales Forecast

Next quarter’s sales forecast for AGIO is $963.08M with a range of $878.13M to $1.03B. The previous quarter’s sales results were $836.00M. AGIO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year AGIO has Performed in-line its overall industry.

AGIO Stock Forecast FAQ

What is MX:AGIO’s average 12-month price target, according to analysts?

Based on analyst ratings, Agios Pharma’s 12-month average price target is 844.50.

What is MX:AGIO’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for MX:AGIO, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Agios Pharma a Buy, Sell or Hold?

Agios Pharma has a consensus rating of Strong Buy, which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.

What is Agios Pharma’s share price target?

The average share price target for Agios Pharma is 844.50. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $1,027.60 ,and the lowest forecast is $597.87. The average share price target represents -30.89% Decrease from the current price of $1,222.

What do analysts say about Agios Pharma?

Agios Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of Agios Pharma?

To buy shares of MX:AGIO, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Agios Pharma (AGIO) Stock Forecast & Price Target

AGIO Analyst Ratings

AGIO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Agios Pharma

AGIO Analyst Recommendation Trends

AGIO Financial Forecast

AGIO Earnings Forecast

AGIO Sales Forecast

AGIO Stock Forecast FAQ

Detailed List of Analyst Forecasts